Quick Answer
Ergothioneine Blood Pressure Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: Aim To investigate the association between serum ergothioneine and risk of developing dementia and its subtypes in a community-dwelling older population.
Key Takeaways
- 01Aim To investigate the association between serum ergothioneine and risk of developing dementia and its subtypes in a community-dwelling older population. [Meng X (2025)]
- 02Cox proportional hazards models were used to estimate the hazard ratios (HRs) and their 95% confidence intervals for the association between serum ergothioneine levels and the risk of dementia subtypes. [Meng X (2025)]
- 03The age- and sex-adjusted HRs for all-cause dementia, AD, and non-AD dementia decreased progressively across increasing quartiles of serum ergothioneine (all P for trend Conclusions Our findings showed that higher serum ergothioneine levels were associated with a lower risk of developing all-cause dementia, AD, and non-AD dementia in an older Japanese population. [Meng X (2025)]
- 04Methods In this prospective longitudinal analysis of participants enrolled in the Hisayama Study, 1344 Japanese community-residents aged 65 years and over without dementia at baseline were followed prospectively for a median of 11.2 years (2012-2023). [Meng X (2025)]
The current Migaku evidence database contains 2 reusable source documents for Ergothioneine Blood Pressure Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts.
- Aim To investigate the association between serum ergothioneine and risk of developing dementia and its subtypes in a community-dwelling older population. [Meng X (2025); evidence level 4]
- Cox proportional hazards models were used to estimate the hazard ratios (HRs) and their 95% confidence intervals for the association between serum ergothioneine levels and the risk of dementia subtypes. [Meng X (2025); evidence level 4]
- The age- and sex-adjusted HRs for all-cause dementia, AD, and non-AD dementia decreased progressively across increasing quartiles of serum ergothioneine (all P for trend Conclusions Our findings showed that higher serum ergothioneine levels were associated with a lower risk of developing all-cause dementia, AD, and non-AD dementia in an older Japanese population. [Meng X (2025); evidence level 4]
- Methods In this prospective longitudinal analysis of participants enrolled in the Hisayama Study, 1344 Japanese community-residents aged 65 years and over without dementia at baseline were followed prospectively for a median of 11.2 years (2012-2023). [Meng X (2025); evidence level 4]
- This is particularly important for at-risk populations such as Apolipoprotein E () ε4 allele carriers (), those with a family history of dementia (), and those at an early stage of cognitive decline, known as Subjective Cognitive Decline (SCD) (). [Shan Jiatong (2025); evidence level 4]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources